VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group von Zervas, K, Mihou, D, Katodritou, E, Pouli, A, Mitsouli, CH, Anagnostopoulos, A, Delibasi, S, Kyrtsonis, MC, Anagnostopoulos, N, Terpos, E, Zikos, P, Maniatis, A, Dimopoulos, MA

Volltext

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study von Zervas, K., Dimopoulos, M. A., Hatzicharissi, E., Anagnostopoulos, A., Papaioannou, M., Mitsouli, Ch, Panagiotidis, P., Korantzis, J., Tzilianos, M., Maniatis, A.

Volltext